Copper is correct. Margin for long purchase is always 50% (federal reqt). Maintainence % is variable for each broker according to many variables which the margin dept sets according to, among other things, concentration of shares in a clients acct in comparison to shares held at the broker. It can be as low as 25% or higher. Shares are sold as chosen by the broker to settle a margin call. You do not get credit for the call should the market go back up. But, for more sophisticated accts, part of your acct is a 'special memorandum acct" or SMA, which is kept by the broker to indicate "money" which can be applied as a credit to margin maintenance. So a sudden drop in stock price need not cause a margin call.
I think you are right researcher. Deliver results as promised; don't create suspicion that all is not well by expanding a study (even phase 1). WS always suspects problems!
Yep. First cc question about why 14 day study. Brilliant answer from straight-shooter Dr. Sheridan; no hesitation or voice inflections. But now we are stuck with the $2 drop for a while. That's WS for you. Drop like a rock, and even if the drop is for BS reasons which are immediately dispelled by management, slow recovery.
Devil's advocate: could the combination of the new 14-day treatment cohort and the announcement of 3 new inhibitor molecules to pre-clinical work possibly be infering that 7353 has problems? You know that WS shoots first and asks questions later.
It's very odd that pre-opening price was up to 15 at first and then fell like a rock.
Not if the CNBC hit jobs of Tues and Friday are successful - technical "graveyard doji". Where do they get this bull.
Been here 7 years. First caught my eye because of their relationship with Southern Research Institute. Sometimes you have to be strong and patient for a long time.
6% diarrhea for Linzess vs 4% for Synergy. This is major?
Both companies drugs are only 30% effective.
Barrons completely discounts Ironwoods' pipeline.
Synergy is at least a year away from marketing. Linzess has the market almost to itself right now.
Typical WS over reaction.
The other part of this that has me thinking seriously about reducing my position is the ridiculous rush to buy AXON. This "company" buys a $5 M castaway from big pharma using shell companies, and then does an IPO, and mucho suckers double the initial price in one day. Their drug has no useful data to look at. Can you say biotech bubble? BCRX, in spite of its strong technology, will get carried along in the event of a bust.
So, dfgall, watch carefully.
I've been taking 10% off with every dollar increase. We've all seen this baby go suddenly down before; and, well, just not taking any chances this time.
Bird flu approaching Pennsylvania. Very serious threat. Not affecting BCRX pps, apparently, unless hovering around $13 is the flu effect.
Let's depend on the geniouses in Congress. They'll debate who should pay for the drug development. By then, the pandemic will be over.
" Recall that AG alone achieved a PFS of 5.5 mos and OS of 8.5 mos in phase III in an
If this is what is possible in an unselected population, then OS 10 months in a high hyaluronan population is not wonderful, eh?